Ginwa Enterprise Group Inc
600080
Company Profile
Business description
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
Contact
Gaoxin 3rd Road
40th Floor, South Tower, Phase III
Fortune Center
Gaoxin District
Xi'an710075
CHNT: +86 2988336635
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
588
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,212.10 | 63.00 | 0.69% |
| CAC 40 | 7,924.23 | 53.89 | 0.68% |
| DAX 40 | 24,449.55 | 72.05 | 0.30% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,167.20 | 10.04 | -0.11% |
| HKSE | 25,270.07 | 249.25 | -0.98% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
| NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
| SSE Composite Index | 3,696.77 | 30.33 | 0.83% |